Glucotrack, Inc. 8K

Glucotrack, Inc. agreed to acquire Lokahi Therapeutics, Inc. via a merger in which Lokahi’s owners will receive mostly convertible preferred stock and obtain 90% post‑merger ownership of Glucotrack, while Lokahi’s CEO becomes Glucotrack’s CEO and the company implements related financing and Nasdaq compliance measures.

On July 14, 2026, Glucotrack, Inc. entered into an Agreement and Plan of Merger with its wholly owned Nevada subsidiary Glucotrack Merger Sub, Inc. and Lokahi Therapeutics, Inc., under which Merger Sub will merge with and into Lokahi, with Lokahi surviving as a wholly owned subsidiary of Glucotrack; in connection with the transaction, Glucotrack will issue common and newly created Series A Convertible Preferred Stock so that former Lokahi stockholders collectively own 90% of Glucotrack’s fully diluted equity (subject to a 10% floor for existing Glucotrack stockholders) and Erik Emerson, Lokahi’s CEO, will become CEO and a director of Glucotrack while Paul V. Goode becomes CEO of Glucotrack Technologies Inc., all as part of a broader financing and Nasdaq listing maintenance plan that includes a PIPE, bridge financings, and an equity line of credit.

Filing Facts

CIK

1506983

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-033393

Alert Tier

8